Statistical significance acheived at all three doses in primary endpoint of Phase III trial 11/06

FDA OK'd changes to ongoing ARISE trial 1/05; Phase III ARISE trial failed to show significance but did meet secondary endpoints 3/07

Began pivotal Phase III TRIUMPH trial 6/05

Phase III data showed the drug caused a significant reduction in cardiovascular hospitalizations 11/07; significantly reduced hospitalization and death among patients with very favorable geno-types; FDA accepted an NDA 9/08; pivotal data showed it narrowly missed the endpoint of providing an overall survival benefit 3/09

Reached an agreement with the FDA on an SPA for a Phase III trial 9/08

Pivotal data showed it increased and sustained platelet counts with extended treatment and reduced the need for concurrent and rescue ITP medications 6/08; FDA granted approval 8/08

Began Phase III trial 9/05

Phase III data showed nearly 50% less bleeding at 30 days and comparable mortality at one year when patients were treated with Angiox vs. unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIainhibitor; FDA accepted company's sNDA 9/07; received European Commission approval for an expanded use in adult patients 1/08; received a not-approvable letter of an sNDA for an additional dosing regimen 5/08